Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis

Abstract

In active RA patients with an incomplete MTX response, CZP 200 mg every 2 weeks and 400 mg every 4 weeks were comparable and better than placebo for maintaining clinical response to week 4 following a 16-week, open-label run-in phase.